Intrommune Therapeutics Presents Oral Mucosal Immunotherapy Updates at Leading Industry Events
May 21, 2024 09:35 ET
|
Intrommune Therapeutics
Intrommune Therapeutics Presents Oral Mucosal Immunotherapy Updates at Leading Industry Events
Intrommune Therapeutics To Present A New Form Of Allergy Treatment At The 2024 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
February 06, 2024 09:34 ET
|
Intrommune Therapeutics
New study is the first to evaluate Oral Mucosal Immunotherapy (OMIT) for the treatment of food allergy
Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy
January 08, 2024 09:05 ET
|
Intrommune Therapeutics
Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy
Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment of Peanut Allergy
November 09, 2023 11:01 ET
|
Intrommune Therapeutics
Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment Peanut Allergy
Intrommune Therapeutics Completes Last Patient Last Visit in the Phase 1 OMEGA Study for Peanut Allergy
July 25, 2023 09:35 ET
|
Intrommune Therapeutics
NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Intrommune Therapeutics Completes Enrollment in the Phase 1 OMEGA Study for Peanut Allergy
October 26, 2022 09:35 ET
|
Intrommune Therapeutics
Observed only mild and transient adverse events, with no use of emergency epinephrine Observed 98.4% patient compliance to date with novel OMIT therapeutic modality Safely started patients on dose...
Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy
June 22, 2022 09:31 ET
|
Intrommune Therapeutics
Amendment to Extend Study Duration to 48 weeks New Maintenance Period Is Designed to Evaluate Safety of INT301 After Long-term Exposure NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune...
Intrommune to Participate in BIO @ JPM During “J.P. Morgan Week 2021”
January 07, 2021 17:35 ET
|
Intrommune Therapeutics
NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, will...
Intrommune Therapeutics Strikes Deal with Circuit Clinical®
October 20, 2020 10:00 ET
|
Intrommune Therapeutics
NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Intrommune Therapeutics has announced an expanded partnership with Circuit Clinical, a leading Integrated Research Organization (IRO). Based on this deal,...
Recent Peer-Reviewed Publication Supports Immunotherapy for the Treatment of Food Allergies
October 08, 2020 09:50 ET
|
Intrommune Therapeutics
NEW YORK, Oct. 08, 2020 (GLOBE NEWSWIRE) -- A recent publication in the journal Immunotherapy reviews a variety of immunotherapy platforms for the treatment of food allergies. The article,...